Abstracts - faqs.org

Abstracts

Retail industry

Search abstracts:
Abstracts » Retail industry

A bitter pill to swallow

Article Abstract:

British Biotech was once regarded as one of the UK's most promising companies, but it now faces an uncertain future. The company came into conflict with Andrew Millar, head of research, and saw a dramatic fall in its share price. It has been necessary to abandon the anti-pancreatitis treatment Zacutex following inconclusive trials, and the company has also been negatively affected by disappointing results for the anti-cancer drug Marimastat. New Chief Executive Elliot Goldstein now plans a return to basics.

Author: Guerrera, Francesco
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1999
United Kingdom, Strategy & planning

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Millar condemns Biotech's drugs

Article Abstract:

British Biotech has denied allegations from former head of clinical research Andrew Millar that it is running short of money. The company has also rejected Millar's claims that the chance of Marimastat, one of its key products, being successful is only around 40%. Millar has stated that the board of British Biotech is being far too optimistic, particularly in relation to Zacutex, another key drug. He was dismissed for allegedly breaching confidentiality clauses in his contract by talking to shareholders.

Author: Macalister, Terry
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1998
Beliefs, opinions and attitudes, Millar, Andrew

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


UK biotech loses formula for success

Article Abstract:

A crisis of confidence has emerged in the UK biotechnology sector following a series of disappointing drug tests. There are now growing signs that this crisis could have a negative impact on the long-term prospects for biotechnology companies. The share prices of these companies have declined dramatically, and new biotechnology companies are finding it increasingly difficult to raise funds to pay for costly research programmes.

Author: Guerrera, Francesco
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1998
Economic aspects

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Management, Biotechnology industry, Biotechnology industries, Biochemistry, British Biotech PLC
Similar abstracts:
  • Abstracts: The pregnant pause. A bitter pill to swallow
  • Abstracts: Why we are not wrong to compare Milosevic to Hitler. Is there a magic formula for peace in the Balkans?
  • Abstracts: Did the earth move for you? The excessive minimalist. The Vulcan has landed
  • Abstracts: The body snatcher. But mum, we really want to wear uniforms. Hello. I'm your worst nightmare
  • Abstracts: Brother John Sellers. This one's from the heart
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.